{"url_path":"/sec/abcl/8-k/2026-06-17/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1703057/0001703057-26-000035-index.html","accession_number":"0001703057-26-000035","cik":"0001703057","ticker":"ABCL","issuer_name":"AbCellera Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1703057/0001703057-26-000035-index.html","primary_entity_key":"0001703057","primary_entity_name":"AbCellera Biologics Inc."},"word_count":83,"has_tables":true,"body_markdown":"Item 8.01 Other Events\n\nOn June 17, 2026, AbCellera Biologics Inc. (the “Company”) issued a press release announcing a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will leverage AbCellera’s antibody discovery engine to deliver optimized development candidates for multiple gastrointestinal (GI) cancers and other solid tumors. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference."}